CA3177202A1 - Systeme a ultra-violet a (uva) et a ultra-violet c (uvc) et methodes pour l'inactivation, la reduction et l'inhibition de la croissance du coronavirus - Google Patents
Systeme a ultra-violet a (uva) et a ultra-violet c (uvc) et methodes pour l'inactivation, la reduction et l'inhibition de la croissance du coronavirusInfo
- Publication number
- CA3177202A1 CA3177202A1 CA3177202A CA3177202A CA3177202A1 CA 3177202 A1 CA3177202 A1 CA 3177202A1 CA 3177202 A CA3177202 A CA 3177202A CA 3177202 A CA3177202 A CA 3177202A CA 3177202 A1 CA3177202 A1 CA 3177202A1
- Authority
- CA
- Canada
- Prior art keywords
- light source
- uvc
- uva
- uvc light
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 42
- 241000711573 Coronaviridae Species 0.000 title abstract description 42
- 230000002779 inactivation Effects 0.000 title description 14
- 230000009467 reduction Effects 0.000 title description 4
- 230000017066 negative regulation of growth Effects 0.000 title description 2
- 210000001508 eye Anatomy 0.000 claims abstract description 20
- 210000002615 epidermis Anatomy 0.000 claims abstract description 18
- 210000004207 dermis Anatomy 0.000 claims abstract description 17
- 230000001603 reducing effect Effects 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000002939 deleterious effect Effects 0.000 claims abstract description 6
- 244000309467 Human Coronavirus Species 0.000 claims description 21
- 230000002829 reductive effect Effects 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 8
- 230000001351 cycling effect Effects 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 64
- 241000711467 Human coronavirus 229E Species 0.000 description 48
- 230000000694 effects Effects 0.000 description 22
- 241001678559 COVID-19 virus Species 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 230000000120 cytopathologic effect Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 241000315672 SARS coronavirus Species 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 230000002458 infectious effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000013207 serial dilution Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000012864 cross contamination Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 238000011053 TCID50 method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000011060 control of substances hazardous to health Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009349 indirect transmission Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/24—Apparatus using programmed or automatic operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/11—Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
L'invention concerne un système à UVA/UVC destiné à réduire les taux actifs, sur une surface, et à inhiber la croissance supplémentaire du coronavirus sur ladite surface, ledit système n'ayant pas d'effets délétères sur un humain, en particulier sur l'il humain ou l'épiderme et le derme humains, ledit système comprenant : iv) au moins une source de lumière UVA ; v) au moins une source de lumière UVC ; et au moins un dispositif de commande connecté à chaque source parmi ladite au moins une source de lumière UVA et ladite au moins une source de lumière UVC, pour commander au moins un paramètre de chaque source parmi la source de lumière UVA et la source de lumière UVC.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019534P | 2020-05-04 | 2020-05-04 | |
| US63/019,534 | 2020-05-04 | ||
| PCT/CA2020/051059 WO2021174331A1 (fr) | 2020-03-03 | 2020-07-31 | Système combiné d'ultra-violet a (uva) et d'ultra-violet c (uvc) pour la réduction et l'inhibition de la croissance d'agents pathogènes |
| CAPCT/CA2020/051059 | 2020-07-31 | ||
| US16/984,366 US20210275705A1 (en) | 2020-03-03 | 2020-08-04 | Combination ultra-violet a (uva) and ultra-violet c (uvc) system for reduction and inhibition of growth of pathogens |
| US16/984,366 | 2020-08-04 | ||
| PCT/CA2021/050543 WO2021223012A1 (fr) | 2020-05-04 | 2021-04-20 | Système à ultra-violet a (uva) et à ultra-violet c (uvc) et méthodes pour l'inactivation, la réduction et l'inhibition de la croissance du coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177202A1 true CA3177202A1 (fr) | 2021-11-11 |
Family
ID=78467852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177202A Pending CA3177202A1 (fr) | 2020-05-04 | 2021-04-20 | Systeme a ultra-violet a (uva) et a ultra-violet c (uvc) et methodes pour l'inactivation, la reduction et l'inhibition de la croissance du coronavirus |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4146289A1 (fr) |
| CA (1) | CA3177202A1 (fr) |
| WO (1) | WO2021223012A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018132671A1 (fr) * | 2017-01-12 | 2018-07-19 | UD Innovations, LLC | Appareil, procédé et système d'irradiation germicide hybride à position fixe |
| CA3050002A1 (fr) * | 2017-01-12 | 2018-07-19 | UD Innovations, LLC | Appareil portable de desinfection par uv-c, procede et systeme |
| WO2019072205A1 (fr) * | 2017-10-11 | 2019-04-18 | The Hong Kong University Of Science And Technology | Éclairage intermittent asynchrone pour une désinfection de surface rapide |
| WO2019084264A2 (fr) * | 2017-10-25 | 2019-05-02 | Sensor Electronic Technology, Inc. | Dispositif d'éclairage à source de lumière ultraviolette et bleue-ultraviolette |
| US11938236B2 (en) * | 2018-08-17 | 2024-03-26 | Seoul Viosys Co., Ltd. | Medical dressing |
-
2021
- 2021-04-20 EP EP21799470.6A patent/EP4146289A1/fr active Pending
- 2021-04-20 CA CA3177202A patent/CA3177202A1/fr active Pending
- 2021-04-20 WO PCT/CA2021/050543 patent/WO2021223012A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP4146289A1 (fr) | 2023-03-15 |
| WO2021223012A1 (fr) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kitagawa et al. | Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination | |
| Chiappa et al. | The efficacy of ultraviolet light-emitting technology against coronaviruses: a systematic review | |
| Bentley et al. | Hydrogen peroxide vapour decontamination of surfaces artificially contaminated with norovirus surrogate feline calicivirus | |
| Darnell et al. | Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products | |
| Park et al. | Simultaneous comparison of murine norovirus, feline calicivirus, coliphage MS2, and GII. 4 norovirus to evaluate the efficacy of sodium hypochlorite against human norovirus on a fecally soiled stainless steel surface | |
| KR101426570B1 (ko) | 부유 바이러스 감염 대책 방법 | |
| Krug et al. | Chemical disinfection of high-consequence transboundary animal disease viruses on nonporous surfaces | |
| Shimoda et al. | Efficacy of 265-nm ultraviolet light in inactivating infectious SARS-CoV-2 | |
| De Santis et al. | Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths | |
| AU2018247584A1 (en) | Apparatus and methods for irradiating organ perfusates | |
| Mohammed et al. | 2019 novel coronavirus disease (covid-19): Toward a novel design for disinfection robot to combat coronavirus (covid-19) using iot based technology | |
| Uema et al. | Effect of the photocatalyst under visible light irradiation in SARS-CoV-2 stability on an abiotic surface | |
| US20230063654A1 (en) | Ultra-violet a (uva) and ultra-violet c (uvc) system and methods for inactivation, reduction and inhibition of growth of coronavirus | |
| KR20010108199A (ko) | 광역-스펙트럼 펄스광을 사용하는 병원체의 불활성화 방법 | |
| CA3177202A1 (fr) | Systeme a ultra-violet a (uva) et a ultra-violet c (uvc) et methodes pour l'inactivation, la reduction et l'inhibition de la croissance du coronavirus | |
| Sahun et al. | Inactivation of SARS-CoV-2 and other enveloped and non-enveloped viruses with non-thermal plasma for hospital disinfection | |
| Olagüe et al. | Rapid SARS-CoV-2 disinfection on distant surfaces with UV-C: The inactivation is affected by the type of material | |
| Scholte et al. | Exploring inactivation of SARS-CoV-2, MERS-CoV, Ebola, Lassa, and Nipah viruses on N95 and KN95 respirator material using photoactivated methylene blue to enable reuse | |
| Su et al. | Resistance of poliovirus 1 and enterovirus A71 against alcohol and other disinfectants | |
| Ruetalo et al. | Rapid and efficient inactivation of surface dried SARS-CoV-2 by UV-C irradiation | |
| Antas et al. | Effective inactivation of porcine epidemic diarrhea virus on contaminated surgery masks by low-concentrated sodium hypochlorite dispersion | |
| EP3078740A1 (fr) | Procédé d'inactivation d'arn et d'adn comprenant des virus sur des instruments médicaux et installation de mise en uvre | |
| Demak et al. | Can Autonomous UV Disinfection Robots Sterilize a Room? A Review. | |
| Singh et al. | Spectacular effects of ultraviolet C radiation, gamma radiation, X-ray radiation & heat treatment on disinfection rate of SARS-COVID virus-2 | |
| Varghese et al. | COVID-19: UV SANITIZER KIT FOR REUSABLE N95 MEDICAL MASK USING HYDROGEN PEROXIDE VAPORIZATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |